Avita Medical (RCEL)
(Delayed Data from NSDQ)
$9.34 USD
+0.57 (6.50%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $9.35 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.34 USD
+0.57 (6.50%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $9.35 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Zacks News
Avita (RCEL) Falls 19% on Lowered 2023 Revenue Guidance
by Zacks Equity Research
Avita's (RCEL) stock declines 19% after the company lowered its total revenue guidance for 2023.
Strength Seen in Avita Medical Inc. (RCEL): Can Its 20.4% Jump Turn into More Strength?
by Zacks Equity Research
Avita Medical Inc. (RCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
AVITA (RCEL) Gets FDA Nod for Expanded Use of RECELL System
by Zacks Equity Research
AVITA (RCEL) surges on FDA approval for expanded use of its RECELL System to treat full-thickness skin defects.
Here's Why Momentum in Avita Medical Inc. (RCEL) Should Keep going
by Zacks Equity Research
Avita Medical Inc. (RCEL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Indaptus (INDP) Surges on Upbeat Pre-Clinical Decoy Data
by Zacks Equity Research
Indaptus (INDP) announces positive pre-clinical efficacy data from a poster presentation made at a scientific conference from its proprietary Decoy platform pre-clinical study. Stock is up 22%.
What Makes Avita Medical Inc. (RCEL) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Avita Medical Inc. (RCEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Novo Nordisk (NVO) Increases Sales & Operating Profit Guidance
by Zacks Equity Research
Novo Nordisk (NVO) increases annual guidance for the year 2023 on higher sales expectations for Ozempic and Wegovy.
Novo (NVO) & Aspect Biosystems Unite to Develop Tissue Therapy
by Zacks Equity Research
Pharma Goliath Novo Nordisk (NVO) inks collaboration agreement with Aspect Biosystems to develop and commercialize transformative cell therapy treatments for type I diabetes patients.
Aurinia (AUPH) Up 11% on Issue of New Additional Lupkynis Patent
by Zacks Equity Research
Aurinia Pharmaceuticals (AUPH) announces the issue of its new and refined method-of-use patent, supplementing its existing patent, for Lupkynis to treat lupus nephritis. Shares are up 11%.
Here's What Could Help Avita Medical Inc. (RCEL) Maintain Its Recent Price Strength
by Zacks Equity Research
Avita Medical Inc. (RCEL) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Pacira's (PCRX) sNDA for Exparel Accepted for FDA Review
by Zacks Equity Research
The FDA accepts Pacira's (PCRX) sNDA filing, which seeks to expand the label of its pain drug Exparel to include both sciatic and femoral nerve blocks. A final decision is expected by November 2023.
Novo Nordisk (NVO) Meets Semaglutide Higher Dosage Study Goal
by Zacks Equity Research
Novo Nordisk (NVO) announces positive top-line results from its phase III increased dosage study of semaglutide, 25 mg and 50 mg, for the treatment of patients with type II diabetes.
89bio (ETNB) Up 25% on Upbeat Data From Mid-Stage NASH Study
by Zacks Equity Research
Data from a phase IIb study showed that treatment with 89bio's (ETNB) lead candidate improved fibrosis improved fibrosis at 3.5 times the rate of the placebo without worsening NASH.
BridgeBio Pharma (BBIO) Surges 77% YTD: Here's Why
by Zacks Equity Research
Shares of BridgeBio (BBIO) are up rising since the company announced positive data from a mid-stage study, which evaluated its experimental drug infigratinib in children with achondroplasia, a form of dwarfism.
Altimmune (ALT) Stock Down Despite Positive Obesity Study Data
by Zacks Equity Research
Altimmune (ALT) reports positive interim analysis data from a phase II obesity study of pemvidutide. However, the stock dropped about 55% likely due to concerns regarding the high discontinuation rate.
Karuna's (KRTX) KarXT Meets Primary Goal in Schizophrenia Study
by Zacks Equity Research
Data from a late-stage study shows that treatment with Karuna's (KRTX) lead candidate, KarXT, led to an early and sustained statistically significant reduction of symptoms of schizophrenia.
Esperion (ESPR) Plummets 54% Over Milestone Payment Row
by Zacks Equity Research
An SEC filing by Esperion (ESPR) reveals that partner Daiichi Sankyo disagrees with the company's assessment that cardiovascular outcome CLEAR study data would support milestone payments.
Merck's (MRK) Co-formulation Therapy Fails Lung Cancer Study
by Zacks Equity Research
Data from a mid-stage study showed that Merck's (MRK) MK-7684A did not improve progression-free survival as a potential treatment for patients with metastatic non-small cell lung cancer.
Catalyst's (CPRX) Q4 Earnings & Sales Top, Boosted by Firdapse
by Zacks Equity Research
Catalyst Pharmaceuticals (CPRX) reports better-than-expected financial performance as it beats both earnings and revenue estimates. Firdapse sales continue to grow year over year.
What Makes Avita Medical Inc. (RCEL) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Avita Medical Inc. (RCEL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
How Much Upside is Left in Avita Medical Inc. (RCEL)? Wall Street Analysts Think 27.42%
by Zacks Equity Research
The mean of analysts' price targets for Avita Medical Inc. (RCEL) points to a 27.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Pacira's (PCRX) Q4 Earnings Match Estimates, Revenues Fall
by Zacks Equity Research
Pacira BioSciences (PCRX) reports mixed fourth-quarter financial results, where earnings match estimates, but revenues miss the mark.
Here's Why 'Trend' Investors Would Love Betting on Avita Medical Inc. (RCEL)
by Zacks Equity Research
Avita Medical Inc. (RCEL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Avita Medical Inc. (RCEL) Stock Jumps 6.2%: Will It Continue to Soar?
by Zacks Equity Research
Avita Medical Inc. (RCEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Wall Street Analysts See a 127% Upside in Avita Medical Inc. (RCEL): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 127.1% in Avita Medical Inc. (RCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.